Impact Biomedical IBO
NYSE IBO
$5.14 +0.35 (+7.31%)
At close: Nov 13, 2026 · 4:00 PM EST

Impact Biomedical (IBO) Gross Profit (2025 - 2026)

Updated

Impact Biomedical (IBO) reported Gross Profit of $15,000 for Q3 2026, down 11.8% from $17,000 a year earlier but up 650.0% from the prior quarter.

Analysis

Impact Biomedical (IBO) Gross Profit (2025 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, Impact Biomedical's Gross Profit came in at -$381,000; for FY2025, it was -$392,000.

  • Five-year quarterly Gross Profit spans a low of -$415,000 in Q4 2025 and a high of $17,000 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Impact Biomedical 43.92 Mn 47.11 Mn 15,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 15,000.00
Jun 30, 2026 2,000.00
Dec 31, 2025 -415,000.00
Sep 30, 2025 17,000.00
Jun 30, 2025 6,000.00
API Access

Impact Biomedical Gross Profit API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-profit&ticker=IBO&period=max&api_key=YOUR_API_KEY